Business Wire

MANIV

4.4.2024 17:21:27 CEST | Business Wire | Press release

Share
Maniv Announces Third Early-stage Venture Fund of $140m to Accelerate the Decarbonization and Digitization of Global Transportation

Maniv, a global venture capital firm based in Tel Aviv and NYC, today announces the closing of its third fund, an $140m vehicle to invest in Seed and Series A stage startups that brings the firm’s assets under management to nearly $320m.

Investing since 2016, Maniv was among the first institutional investors to articulate a global, early-stage investment strategy focused on the intersection between mobility, transportation and energy. Maniv invests in deep technologies and business model innovations around two central themes:

The movement of people and goods continues to be marked by analog processes and data-poor operating environments. From manufacturing to fulfillment and logistics, vehicle access, maintenance and repair, insurance, fleet management, and more, startups are driving the digitization of transportation’s value chains across land, sea, and air. Simultaneously, the market-driven decarbonization of transportation – representing as much as one quarter of global GHG emissions – is at an inflection point. Private sector incentives are tipping towards clean propulsion, a process accelerated by brisk regulatory tailwinds worldwide. These seismic shifts create a massive opportunity for startups to advance new technologies, form factors, business models, and platforms.

Maniv has already made four investments out of the new fund. Celadyne, based in Chicago, extends the lifespan and efficiency of proton-exchange membranes to make green hydrogen production financially viable. Neologic, based in Israel, introduces a proprietary chip design for dramatic performance and power gains in data centers, automotive and beyond. Circular, based in San Francisco, mainstreams post-consumer recycled plastics adoption in manufacturing, by closing pervasive information and testing gaps. Vammo, based in São Paulo, is electrifying LATAM’s B2B two-wheeler market, by orchestrating vehicles, financing, and a ubiquitous battery swapping network.

From its first two, top-performing funds, Maniv led investments in breakout companies including AI edge silicon scaleup Hailo from Tel Aviv, EV ridehail and charging network Revel from New York, medium-duty EV truckmaker Harbinger Motors from Los Angeles, intercity bussing platform Kolors from Mexico City, two-wheeler EV OEM River from Bangalore, and Madrid-based car subscription startup Bipi, acquired by Renault’s financing arm RCI Banque in 2021.

Maniv’s third fund is backed by institutional capital, high-net-worth individuals, and a consortium of industry leaders at the forefront of the transportation sector. Maniv’s prior funds were substantially backed by leading carmakers and Tier-1 suppliers. Maniv III maintains those automotive partnerships – including return investors Valeo and InMotion Ventures, the investment arm of Jaguar-Land Rover, joined by Woven Capital of Toyota Motor Corp. The new fund has expanded its LP base to reflect critical automotive adjacencies through partners including global vehicle leasing and mobility solutions leader Arval and the automotive finance experts of BNP Paribas Personal Finance of Europe’s leading bank BNP Paribas; Shell Ventures of the global energy giant Shell; global sustainable infrastructure leader Ferrovial; Enterprise Mobility Ventures, the VC arm of Enterprise Mobility; industrial manufacturing leader ITT Inc.; fleet payments leader WEX; a major European insurance company; several major automotive dealer and distributor groups; and more.

“Our third fund builds on two decades in the trenches of the global mobility ecosystem,” said Michael Granoff, the firm’s Managing Partner. “Maniv has built a platform to summon the best of two worlds – the agility of a traditional VC, and close proximity to the underlying industries surrounding mobility and transportation. We believe we are uniquely structured to leverage our deep institutional memory and access to industry decision-makers, for the benefit of our portfolio companies and ultimately our investors. Announcing this new vehicle amidst a backdrop of geopolitical uncertainty and shaky private markets is a testament to the resilience of the sector and our strategy.”

“Maniv’s mandate is to deliver outsized returns by joining forces with those rare entrepreneurs with both the vision and tenacity to drive the transportation sector into the 21st century,” added Nate Jaret, General Partner at Maniv. “Human prosperity depends on the seamless and sustainable movement of people and goods; mobility continues to represent a generational opportunity for entrepreneurs and investors alike.”

“When we met Maniv, we had spoken to over 100 investors and operators of electric mobility around the world and nobody – repeat nobody – was more knowledgeable about the space than the Maniv team,” said Jack Sarvary, Co-founder & CEO of portfolio company Vammo based in São Paulo. “Getting them not just onto our cap table but also our board quickly became a priority.”

"From the outset it was clear that Maniv is deeply connected to forward-thinking mobility players,” said Ian Arthurs, Founder & CEO of portfolio company Circular. “Within weeks of our first conversation, the Maniv team found us new enterprise partners and customers in the auto space, which would have taken us months to figure out on our own.”

Website: www.maniv.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404972652/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye